drugset / Trial / NCT02157636
A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma
Phase 1
Completed
30 enrolled
Constellation Pharmaceuticals
The Leukemia and Lymphoma Society · collab
NaSingle-groupOpen-labelTreatment
Summary
Open-label, sequential dose escalation and expansion study of CPI-0610 in patients with previously treated multiple myeloma. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
Timeline
- Start
- 2014-07-15
- Primary completion
- 2016-11-08
- Completion
- 2016-11-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pelabresib | Small molecule | — | — |